HAYA Therapeutics

HAYA Therapeutics develops RNA-guided therapeutics that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease-driving cell states. Its platform combines multimodal functional genomics with proprietary computational tools. Its lead program, HTX-001, has started a Phase 1 clinical trial and received FDA Fast Track Designation.

The website describes collaborations with pharmaceutical partners, including a multi-year collaboration with Eli Lilly and Company focused on lncRNA targets in obesity and related metabolic diseases. Funding is reported as a 25 million USD seed round in 2021 and a 65 million USD Series A in 2025. The website does not describe a product revenue model.

The company was founded in 2019 and has offices in Lausanne, Switzerland and San Diego, California. The careers page lists seven open permanent positions, all in San Diego or Lausanne, spanning R&D, GxP quality assurance, translational science, and human resources.

Product: RNA-guided therapeutic candidates targeting lncRNAs, led by HTX-001, which is in Phase 1 clinical trial.